Conditional TPM3-ALK and NPM-ALK transgenic mice develop reversible ALK-positive early B-cell lymphoma/leukemiaSylvie Giuriato(Université Toulouse III - Paul Sabatier), Fabienne Meggetto(Centre National de la Recherche Scientifique)BloodMarch 12, 201010.1182/blood-2008-06-163386Cited by 32SaveCiteExport RISWatch citationsRelated PapersTargeting autophagy enhances the anti-tumoral action of crizotinib in ALK-positive anaplastic large cell lymphoma|Oncotarget|2015|49ALK+ALCLs induce cutaneous, HMGB-1–dependent IL-8/CXCL8 production by keratinocytes through NF-κB activation|Blood|2012|32NPM-ALK: A Driver of Lymphoma Pathogenesis and a Therapeutic Target|Cancers|2021|23Generation of full-length circular RNA libraries for Oxford Nanopore long-read sequencing|PLoS ONE|2022|17